OptimizeRx Reiterates 2024 Guidance And Expects Revenue To Be At Least $100M (Est $101.458M) With Adjusted EBITDA Of At Least $11M
Portfolio Pulse from Benzinga Newsdesk
OptimizeRx has reiterated its 2024 guidance, expecting revenue to be at least $100 million and adjusted EBITDA of at least $11 million. This is slightly below the estimated revenue of $101.458 million.
August 08, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
OptimizeRx has reiterated its 2024 guidance, expecting revenue to be at least $100 million and adjusted EBITDA of at least $11 million. This is slightly below the estimated revenue of $101.458 million.
The reiteration of guidance provides stability but the revenue expectation is slightly below estimates, which may cause a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100